Synergistic effects of quercetin-loaded CoFe2O4@Liposomes regulate DNA damage and apoptosis in MCF-7 cancer cells: based on biophysical magnetic hyperthermia.

INTRODUCTION: Breast cancer (BC) is the most common malignancy in women globally. Significant progress has been made in developing structural nanoparticles (NPs) and formulations for targeted smart drug delivery (SDD) of pharmaceuticals, improving the precision of tumor cell targeting in therapy. SIGNIFICANCE: Magnetic hyperthermia (MHT) treatment using magneto-liposomes (MLs) has emerged as a promising adjuvant cancer therapy. METHODS: CoFe2O4 magnetic NPs (MNPs) were conjugated with nanoliposomes to form MLs, and the anticancer drug quercetin (Que) was loaded into MLs, forming Que-MLs composites for antitumor approach. The aim was to prepare Que-MLs for DD systems (DDS) under an alternating magnetic field (AMF), termed chemotherapy/hyperthermia (chemo-HT) techniques. The encapsulation efficiency (EE), drug loading capacity (DL), and drug release (DR) of Que and Que-MLs were evaluated. RESULTS: The results confirmed successful Que-loading on the surface of MLs, with an average diameter of 38 nm and efficient encapsulation into MLs (69%). In vitro, experimental results on MCF-7 breast cells using MHT showed high cytotoxic effects of novel Que-MLs on MCF-7 cells. Various analyses, including cytotoxicity, apoptosis, cell migration, western blotting, fluorescence imaging, and cell membrane internalization, were conducted. The Acridine Orange-ethidium bromide double fluorescence test identified 35% early and 55% late apoptosis resulting from Que-MLs under the chemo-HT group. TEM results indicated MCF-7 cell membrane internalization and digestion of Que-MLs, suggesting the presence of early endosome-like vesicles on the cytoplasmic periphery. CONCLUSIONS: Que-MLs exhibited multi-modal chemo-HT effects, displaying high toxicity against MCF-7 BC cells and showing promise as a potent cytotoxic agent for BC chemotherapy.

Actinobacterium-Mediated Green Synthesis of CuO/Zn-Al LDH Nanocomposite Using Micromonospora sp. ISP-2 27: A Synergistic Study that Enhances Antimicrobial Activity.

Bacterial resistance to conventional antibiotics has created an urgent need to develop enhanced alternatives. Nanocomposites combined with promising antibacterial nanomaterials can show improved antimicrobial activity compared to that of their components. In this work, green synthesized CuO nanoparticles (NPs) supported on an anionic clay with a hydrotalcite-like structure such as Zn-Al layered double hydroxide (LDH) nanocomposite were investigated as antimicrobial agents. This nanocomposite was synthesized using Micromonospora sp. ISP-2 27 cell-free supernatant to form CuO NPs on the surface of previously synthesized LDH. The prepared samples were characterized using UV-Vis spectrophotometry, XRD, FTIR, Field emission scanning electron microscopy with EDX, zeta potential, and hydrodynamic particle size. UV-vis spectral analysis of the biosynthesized CuO NPs revealed a maximum peak at 300 nm, indicating their successful synthesis. The synthesized CuO NPs had a flower-like morphology with a size range of 43-78 nm, while the LDH support had a typical hexagonal layered structure. The zeta potentials of the CuO NPs, Zn-Al LDH, and CuO NPs/LDH nanocomposite were -21.4, 22.3, and 30.8 mV, respectively, while the average hydrodynamic sizes were 687, 735, and 528 nm, respectively. The antimicrobial activity of the produced samples was tested against several microbes. The results demonstrated that the nanocomposite displayed superior antimicrobial properties compared to those of its components. Among the microbes tested, Listeria monocytogenes ATCC 7644 was more sensitive (30 ± 0.34) to the biosynthesized nanocomposite than to CuO NPs (25 ± 0.05) and Zn-Al LDH (22 ± 0.011). In summary, the use of nanocomposites with superior antimicrobial properties has the potential to offer innovative solutions to the global challenge of antibiotic resistance by providing alternative treatments, reducing the reliance on traditional antibiotics, and contributing to the development of more effective and targeted therapeutic approaches.